Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-11-03
2011-10-11
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08034812
ABSTRACT:
The present invention provides an imidazopyridazine derivative compound having a potent kinase inhibitory activity and a pharmaceutical agent thereof useful for treatment or prevention of cancer and the like. One such compound is represented by the formula:or a salt thereof or a prodrug thereof. The pharmaceutical agent contains the imidazopyridazine derivative compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor, or a cancer metastasis suppressor.
REFERENCES:
patent: 7723336 (2010-05-01), Vaccaro et al.
patent: 2010/0216798 (2010-08-01), Nakai et al.
patent: 1 153 920 (2001-11-01), None
patent: 1 415 987 (2004-05-01), None
patent: 8-20584 (1996-01-01), None
patent: 89/01333 (1989-02-01), None
patent: 89/01478 (1989-02-01), None
patent: 98/35958 (1998-08-01), None
patent: 00/42012 (2000-07-01), None
patent: 00/43366 (2000-07-01), None
patent: 01/32651 (2001-05-01), None
patent: 01/60814 (2001-08-01), None
patent: 02/32872 (2002-04-01), None
patent: 2005/066177 (2005-07-01), None
patent: 2007/013673 (2007-02-01), None
patent: 2008/016131 (2007-02-01), None
patent: 2007/025090 (2007-03-01), None
patent: 2007/025540 (2007-03-01), None
patent: 2007/038314 (2007-04-01), None
Registry Compound, Oct. 2008.
Bullock, et al., “Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase”, J. Med. Chem. 2005, 48, 7604-7614.
Mourad, et al., “Synthesis of Imidazo[1,2-b]pyridazines: Fenbendazole, Oxifenbendazole Analogs and Related Derivatives”, J. Heterocyclic Chem., 30, 1365-1372, Oct.-Nov. 1993.
Barlin, et al., “Imidazo[1,2-b]pyridazines. II 6-Alkylthio- and 6-Arylthio-3-methoxy- 2-phenylimidazo [1,2-b]pyridazines” Aust. J. Chem., 1987, 40, 1491-7.
Barlin, et al., “Imidazo[1,2-b]pyridazlines IV Syntheses and Central Nervous System Activities of Some 3-Methoxy-6-phenoxy(substituted phenoxy and naphthylocy)-2-phenylimidazo[1,2-b]pyridazines”, Aust. J. Chem, 1988, 41, 1735-42.
Treb{hacek over (s)}e, et al., “A Direct Conversion of 5,6,7,8-Tetrahydro-2H-1-Benzo-Pyran-2,5-Diones into Substituted 1-Amion-5,6,7,8-Tetra-Hydroquinoline-2,5-Diones”, Heterocycles, vol. 59, No. 1, 129-136, 2003.
Treb{hacek over (s)}e, et al., “Transformation of 5-Oxo Substituted Fused Pyran-2-ones. LactamVersusHydrazone Formation”, Synthetic Communications, 27(15), 2637-2644, 1997.
Goli{hacek over (c)} Grdadolnik, et al., “Structural Investigation of 5-Hydrazono-5,6,7,8-tetrahydro-2H-1-benzopyran-2-ones and 5,6,7,8-Tetrahydroquinoline-2,5(1H)-diones”, J. Chem. Inf. Comput. Sci. 1997, 37, 489-494.
Ishikawa, et al., “Synthesis and Antibacterial Activity of 7 β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and Related Compounds”, The Journal of Antibiotics, 54(3), 257-277, Mar. 2001.
Matter, Alex, “Tumor angiogenesis as a therapeutic target”, DDT vol. 6, No. 19, Oct. 2001, pp. 1005-1024.
Ferrara, et al., “The Biology of Vascular Endothelial Growth Factor”, Endocrine Reviews, vol. 18, No. 1, Feb. 1997, pp. 4-25.
Folkamn, Judah, “Tumor Angiogenesis: Therapeutic Implications”, The New England Journal of Medicine, vol. 285, No. 2I, Nov. 1971, pp. 1182-1186.
Barlin, et al., Austral. J. Chem. (1996), 49(4), 443-449 [Barlin (III)].
Stanovnik, et al., Tetrahedron (1967), 23(1), 387-95.
Hirayama Takaharu
Imamura Shinichi
Miyamoto Naoki
Sakai Nozomu
Hamre Schumann Mueller & Larson P.C.
Jaisle Cecilia M
Takeda Pharmaceutical Company Limited
Wilson James O
LandOfFree
Imidazopyridazine derivative having kinase inhibitory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyridazine derivative having kinase inhibitory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyridazine derivative having kinase inhibitory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303195